Arcturus Therapeutics Showcases mRNA Innovations at Jefferies Healthcare Conference 2024

Arcturus Therapeutics: Expanding Horizons in mRNA Medicine

Arcturus Therapeutics Holdings Inc., a prominent player in the messenger RNA (mRNA) medicine landscape, is poised to showcase its innovative approaches at the upcoming Jefferies London Healthcare Conference on November 20, 2024. Scheduled for 9:30 am GMT, the presentation will highlight the company’s strategic advancements in vaccine development and therapeutic treatments for infectious and rare diseases. As a San Diego-based firm founded in 2013, Arcturus has carved a niche for itself by leveraging cutting-edge technologies like LUNAR® lipid-mediated delivery and STARR® mRNA Technology, which have been integral to its success in the field.

A hallmark of Arcturus' achievements is KOSTAIVE®, recognized as the first self-amplifying mRNA COVID-19 vaccine to receive regulatory approval. This innovative vaccine underscores the potential of mRNA technology in addressing public health challenges. The company's commitment to research and development is further exemplified through its collaborations, notably with CSL Seqirus, to create mRNA vaccines. Additionally, the establishment of ARCALIS, a joint venture in Japan, signals Arcturus' ambitions in the global vaccine market, particularly in mRNA therapeutics.

Arcturus Therapeutics boasts a robust pipeline, featuring RNA therapeutic candidates targeting conditions such as ornithine transcarbamylase deficiency and cystic fibrosis. Its partnered mRNA vaccine programs aim to combat SARS-CoV-2 and influenza, reflecting the company’s dedication to addressing critical health issues. With over 400 patents and applications globally, Arcturus stands at the forefront of nucleic acid medicine innovation, showcasing its versatile platforms capable of advancing messenger RNA, small interfering RNA, and gene editing therapeutics.

In addition to the conference presentation, Arcturus maintains an active presence on social media and its Investor Relations website, ensuring stakeholders remain informed about its ongoing projects and partnerships. The company’s focus on developing transformative therapies positions it as a significant contributor to the future of biotechnology and public health initiatives.

As the landscape of mRNA medicine continues to evolve, Arcturus Therapeutics is not only pioneering vaccine technology but is also creating a diverse array of therapeutic solutions that promise to make a significant impact on patient care and disease management globally. The upcoming conference serves as an opportunity for Arcturus to further solidify its role in this dynamic industry, showcasing its innovative spirit and commitment to advancing health solutions.